BioVie

BIVI

Biotechnology · Healthcare

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

BioVie Inc. is a small clinical-stage biotechnology company. It is working on experimental drugs — it does not sell any approved products yet. Its main focus areas are treatments for liver disease (specifically a condition called ascites, where fluid builds up in the abdomen) and neurological disorders like Alzheimer's disease and Parkinson's disease.

BioVie makes no revenue from product sales today. It funds its operations through stock offerings and other financing, which is common for early-stage biotech companies. It operates primarily in the United States and has a very small team. The company has no approved drugs, no commercial moat, and is burning through cash — reflected in its deeply negative returns. The central risk is whether its clinical trials will succeed and whether it can raise enough money to keep running before those results arrive.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-212.5% YoY

YoY Growth Rate

Earnings declining

Insider Activity

0.5%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~0 months

$9M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

BioVie has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-220.6%

Weak — -220.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial